Richard O Chen
Overview
Explore the profile of Richard O Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galsky M, Autio K, Cabanski C, Wentzel K, Graff J, Friedlander T, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39964352
Purpose: Current immune checkpoint therapies offer limited benefits for metastatic castration-resistant prostate cancer (mCRPC). Novel combinations may enhance immunotherapy efficacy. Patients And Methods: We conducted an open-label, non-comparative platform trial...
2.
Black J, Bartha G, Abbott C, Boyle S, Karasaki T, Li B, et al.
Nat Med
. 2025 Jan;
31(1):70-76.
PMID: 39806071
Circulating tumor DNA (ctDNA) detection can predict clinical risk in early-stage tumors. However, clinical applications are constrained by the sensitivity of clinically validated ctDNA detection approaches. NeXT Personal is a...
3.
Nixon A, Navarro F, Zhou K, Abbott C, McDaniel L, Howard L, et al.
Res Sq
. 2025 Jan;
PMID: 39764133
To explore whether ultra-sensitive circulating tumor DNA (ctDNA) profiling enables early prediction of treatment response and early detection of disease progression, we applied NeXT Personal, an ultra-sensitive bespoke tumor-informed liquid...
4.
Tsimberidou A, Alayli F, Okrah K, Drakaki A, Khalil D, Kummar S, et al.
J Exp Med
. 2024 Aug;
221(10).
PMID: 39190534
Identifying pan-tumor biomarkers that predict responses to immune checkpoint inhibitors (ICI) is critically needed. In the AMADEUS clinical trial (NCT03651271), patients with various advanced solid tumors were assessed for changes...
5.
Till J, McDaniel L, Chang C, Long Q, Pfeiffer S, Lyman J, et al.
Nat Commun
. 2024 Jul;
15(1):5763.
PMID: 38982051
While high circulating tumor DNA (ctDNA) levels are associated with poor survival for multiple cancers, variant-specific differences in the association of ctDNA levels and survival have not been examined. Here...
6.
Northcott J, Bartha G, Harris J, Li C, Navarro F, Pyke R, et al.
Oncotarget
. 2024 Jun;
15:407.
PMID: 38900651
No abstract available.
7.
Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay
Northcott J, Bartha G, Harris J, Li C, Navarro F, Pyke R, et al.
Oncotarget
. 2024 Mar;
15:200-218.
PMID: 38484152
We describe the analytical validation of NeXT Personal, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay for detecting residual disease, monitoring therapy response, and detecting recurrence in patients diagnosed with...
8.
Padron L, Maurer D, OHara M, OReilly E, Wolff R, Wainberg Z, et al.
Nat Med
. 2022 Jun;
28(6):1167-1177.
PMID: 35662283
Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating...
9.
Pyke R, Mellacheruvu D, Dea S, Abbott C, McDaniel L, Bhave D, et al.
Nat Commun
. 2022 Apr;
13(1):1925.
PMID: 35414054
Human leukocyte antigen loss of heterozygosity (HLA LOH) allows cancer cells to escape immune recognition by deleting HLA alleles, causing the suppressed presentation of tumor neoantigens. Despite its importance in...
10.
Friedman C, Spencer C, Cabanski C, Panageas K, Wells D, Ribas A, et al.
J Immunother Cancer
. 2022 Jan;
10(1).
PMID: 35074903
Background: There are no validated biomarkers that can aid clinicians in selecting who would best benefit from anticytotoxic T lymphocyte-associated antigen 4 monotherapy versus combination checkpoint blockade in patients with...